ST.
PAUL, Minn., Oct. 8, 2024
/PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf
Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and
CellReady™, today announced that Eric
Tran, Ph.D, Associate Member of the Earle A. Chiles Research
Institute, a division of the Providence Cancer Institute, has been
awarded a G-Rex Grant. Dr. Tran's $200,000 G-Rex Grant will enable process
development and IND enabling studies of a novel KRAS-targeted TCR-T
cell therapy.
"We have utilized G-Rex devices for a long time for our adoptive
cell therapy efforts. This G-Rex Grant will substantially
defray the costs associated with bringing our next generation TCR-T
cell therapy into the clinic and advance the state of our
manufacturing," said Dr. Tran
"Dr. Tran has been contributing to the field of cell and gene
therapy for nearly 15 years and we are grateful for the opportunity
to award a G-Rex Grant to Dr. Tran and the Providence Cancer
Institute. Providence's G-Rex
Grant will help expedite an IND application of their novel
KRAS-targeted TCR T-cell therapy to treat a variety of solid tumors
in a Phase 1/1b clinical trial," said
John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
As part of the G-Rex Grant, Dr. Tran plans to optimize their
manufacturing process by reducing the process duration and
implementing fully-closed system G-Rex bioreactors. Dr. Tran will
make use of Bio-Techne's new GMP cytokines that have been
right-sized for one-touch G-Rex close process manufacturing,
setting the stage for simple and efficient scale out.
ScaleReady's G-Rex® Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain
access to exclusive support from ScaleReady's growing consortium of
G-Rex Grant Partners who bring best-in-class tools and technologies
as well as unparalleled knowledge and expertise in the areas of
cGMP manufacturing, quality and regulatory affairs, CGT business
operations, and more.
About ScaleReady
ScaleReady provides the field of cell
and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 5
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being accomplished
through its scalable G-Rex technology, which is used throughout the
world in CGT applications ranging from basic research to commercial
drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to G-Rex
Bioreactors, including right-sized reagent quantities in containers
that are tailored to high throughput closed-system manufacturing.
For more information on Bio-Techne and its brands, please
visit https://www.bio-techne.com or follow the Company on
social media
at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and
only G-Rex centric contract development and manufacturing
organization (CDMO) specializing in G-Rex based cell and
gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one
G-Rex® process at a time.
About Providence Cancer Institute of Oregon
Providence Cancer Institute of Oregon, a part of Providence St. Joseph
Health, offers the latest in cancer services, including diagnosis,
treatment, prevention, education and support. Providence is home to the Earle A. Chiles
Research Institute, an internationally renowned leader in the field
of cancer immunotherapy since 1993, where investigators lead
numerous clinical trials for patients with cancers of the breast,
colon, prostate, lung, esophagus, liver, pancreas, head and neck,
ovary, skin, blood and other conditions. Learn more
at Providence.org/ORcancer.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute-302269620.html
SOURCE Bio-Techne Corporation